

General information about company

| | |
|-------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|
| Name of The Company | Samrat Pharmachem Limited |
| BSE Scrip Code | 530125 |
| NSE Symbol | |
| MSE Symbol | |
| Date of Start of Financial Year | 01-04-2021 |
| Date of End of Financial Year | 31-03-2022 |
| Reporting Period | First half yearly |
| Date of Start of Reporting Period | 01-04-2021 |
| Date of End of Reporting Period | 30-09-2021 |
| Level of rounding used in financial results | Lakhs |
| Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? | Yes |

| Related party transactions | | | | | |
|------------------------------------------|---|-------------------------------------------------|-----------------------|--------------------------------|-----------------------|
| | | Sr | 1 | 2 | 3 |
| A. Details of related party | | Name of the related party | Lalit Damodar Mehta | Rajesh Lalit Mehta | Megh Rajesh Mehta |
| | | Categories of related parties | Promoters | Promoters | Promoters |
| | | description of relationship | Managing Director | Wholetime Director | Wholetime Director |
| | | PAN of related party | AABPM9691E | AABPM9692H | BWDPM0880Q |
| | | CIN of related party | U99999ZZ9999ZZZ999999 | U99999ZZ9999ZZZ999999 | U99999ZZ9999ZZZ999999 |
| | | B. Details of related party transactions | | Purchase of goods and services | 0 |
| Sale of goods and services | 0 | | | 0 | 0 |
| Purchase of fixed assets | 0 | | | 0 | 0 |
| Sale of fixed assets | 0 | | | 0 | 0 |
| Rendering of services | 0 | | | 0 | 0 |
| Receiving of services | 0 | | | 0 | 0 |
| Leases | 0 | | | 0 | 0 |
| Loans and advances given | 0 | | | 0 | 0 |
| Loans and advances taken | 0 | | | 0 | 0 |
| Loans and advances given that are repaid | 0 | | | 0 | 0 |
| Loans and advances taken that are repaid | 0 | | | 0 | 0 |
| Deposits placed | 0 | | | 0 | 0 |
| Deposits taken | 0 | | | 0 | 0 |
| Transfer of research & development | 0 | | | 0 | 0 |
| Transfers under lease agreement | 0 | | | 0 | 0 |
| Equity investment | 0 | | | 0 | 0 |
| Impairment in equity investment | 0 | | | 0 | 0 |
| Expense for bad or doubtful debts | 0 | | | 0 | 0 |
| Guarantees or collateral | 0 | | | 0 | 0 |

| | | | | | |
|------------------------------------|-------------------------------------------|----------------------------------------------------------------|---------|---------|--------|
| | | given | | | |
| | | Guarantees or collateral taken | 0 | 0 | 0 |
| | | Interest income | 0 | 0 | 0 |
| | | Interest paid | 0 | 0 | 0 |
| | | Dividend income | 0 | 0 | 0 |
| | | Dividend paid | 0 | 0 | 0 |
| | | Management contracts including for deputation of employees | 0 | 0 | 0 |
| | | Settlement of liabilities by entity on behalf of related party | 0 | 0 | 0 |
| | Remuneration | Short term employee benefits | 1800000 | 1500000 | 750000 |
| | | Post employment benefits | 0 | 0 | 0 |
| | | Other long-term benefits | 0 | 0 | 0 |
| | | Termination benefits | 0 | 0 | 0 |
| | | Share based payments | 0 | 0 | 0 |
| | | Others | 0 | 0 | 0 |
| C. Outstanding balances | Receivables | Secured | 0 | 0 | 0 |
| | | Un Secured | 0 | 0 | 0 |
| | Payables | Secured | 0 | 0 | 0 |
| | | Un Secured | 0 | 0 | 0 |
| | Loans and advances | Secured | 0 | 0 | 0 |
| | | Un Secured | 0 | 0 | 0 |
| | given Loans and advances | Secured | 0 | 0 | 0 |
| | | Un Secured | 0 | 0 | 0 |
| | taken Deposits placed | Secured | 0 | 0 | 0 |
| | | Un Secured | 0 | 0 | 0 |
| | Deposits taken | Secured | 0 | 0 | 0 |
| | | Un Secured | 0 | 0 | 0 |
| | Guarantees or collateral | Secured | 0 | 0 | 0 |
| | | Un Secured | 0 | 0 | 0 |
| | given Guarantees or collateral | Secured | 0 | 0 | 0 |
| | | Un Secured | 0 | 0 | 0 |
| | taken Investment in equity | Secured | 0 | 0 | 0 |
| | | Un Secured | 0 | 0 | 0 |
| Provision for doubtful debt | Secured | 0 | 0 | 0 | |
| | Un Secured | 0 | 0 | 0 | |
| Note | | | | | |